Gi Dynamics (GIDYL) 10-Q 14 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 10, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Trading Symbol	GIDYL
Entity Registrant Name	GI DYNAMICS, INC.
Entity Central Index Key	1,245,791
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		15,333,100

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 3,104,000	$ 3,034,000
Restricted cash	30,000	30,000
Accounts receivable, net	0	40,000
Prepaid expenses and other current assets	259,000	265,000
Total current assets	3,393,000	3,369,000
Property and equipment, net	84,000	97,000
Total assets	3,477,000	3,466,000
Current liabilities:
Accounts payable	749,000	1,191,000
Accrued expenses	1,516,000	1,021,000
Deferred revenue	11,000	11,000
Short term debt to related party, net	4,985,000	4,929,000
Total current liabilities	7,261,000	7,152,000
Warrant liability	16,000	29,000
Long term debt to related party, net	96,000
Total liabilities	7,373,000	7,181,000
Commitments (Note 11)
Stockholders’ deficit:
Preferred stock, $0.01 par value – 500,000 shares authorized; no shares issued and outstanding at September 30, 2018 and December 31, 2017
Common stock, $0.01 par value – 50,000,000 shares authorized at September 30, 2018 and December 31, 2017, respectively; 15,333,100 and 11,157,489 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	154,000	112,000
Additional paid-in capital	260,695,000	255,294,000
Accumulated deficit	(264,745,000)	(259,121,000)
Total stockholders’ deficit	(3,896,000)	(3,715,000)
Total liabilities and stockholders’ deficit	$ 3,477,000	$ 3,466,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	500,000	500,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	15,333,100	11,157,489
Common stock, shares outstanding	15,333,100	11,157,489

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Revenue	$ 0	$ 23,000	$ 0	$ 173,000
Cost of revenue		15,000		223,000
Gross loss		8,000		(50,000)
Operating expenses:
Research and development	494,000	960,000	1,121,000	3,010,000
Sales and marketing	167,000	494,000	683,000	1,474,000
General and administrative	1,338,000	1,095,000	3,378,000	3,624,000
Total operating expenses	1,999,000	2,549,000	5,182,000	8,108,000
Loss from operations	(1,999,000)	(2,541,000)	(5,182,000)	(8,158,000)
Other income (expense):
Interest income	7,000	13,000	23,000	25,000
Interest expense	(201,000)	(82,000)	(489,000)	(100,000)
Foreign exchange gain (loss)	2,000		10,000	(6,000)
Other income				23,000
Re-measurement of warrant liability	10,000	7,000	13,000	(33,000)
Other income (expense), net	(182,000)	(62,000)	(443,000)	(91,000)
Loss before income tax expense	(2,181,000)	(2,603,000)	(5,625,000)	(8,249,000)
(Benefit from) Provision for income taxes	2,000	6,000	(1,000)	9,000
Net loss	$ (2,183,000)	$ (2,609,000)	$ (5,624,000)	$ (8,258,000)
Basic and diluted net loss per common share	$ (0.17)	$ (0.23)	$ (0.46)	$ (0.74)
Weighted-average number of common shares used in basic and diluted net loss per common share	12,691,797	11,157,489	12,279,294	11,143,773

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Operating activities:
Net loss				$ (5,624)	$ (8,258)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization				11	46
Loss on disposal of leasehold improvements				2
Amortization of debt issuance costs non-cash interest expense				141	25
Non-cash interest expense				249	73
Accretion of debt discount				96
Stock-based compensation expense				86	162
Re-measurement of warrant liability		$ (10)	$ (7)	(13)	33
Change in inventory reserve					(76)
Changes in operating assets and liabilities:
Accounts receivable				40	(11)
Prepaid expenses and other current assets				6	53
Inventory					289
Accounts payable				(442)	122
Accrued expenses				246	(105)
Net cash used in operating activities				(5,202)	(7,647)
Investing activities
Purchases of property and equipment					(5)
Net cash used in investing activities					(5)
Financing activities
Proceeds from issuance of common stock, net of issuance costs	$ 200			3,607	198
Debt issuance costs				(85)	(115)
Proceeds from long term debt, related party				1,750	5,000
Payments on short term note payable					(214)
Net cash provided by financing activities				5,272	4,869
Net increase (decrease) in cash and cash equivalents				70	(2,783)
Cash, cash equivalents and restricted cash at beginning of period	$ 8,323			3,064	8,323	$ 8,323
Cash, cash equivalents and restricted cash at end of period		$ 3,134	$ 5,540	3,134	5,540	$ 3,064
Supplemental cash flow disclosures
Income taxes paid				25	31
Effect on retained earnings of adopting ASU No. 2016-09 in 2017					$ 28
Beneficial conversion feature discount associated with 2018 Note				1,007
Relative fair value of warrant issued with 2018 Note				$ 743

Nature of Business

Nature of Business	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Nature of Business	1. Nature of Business GI Dynamics, Inc. (the “Company”) was incorporated on March 24, 2003, as a Delaware corporation, with operations based in Boston, Massachusetts. GI Dynamics is a clinical stage medical device company focused on the development and commercialization of EndoBarrier, a medical device indicated for treatment of patients with type 2 diabetes and obesity or obesity alone. Diabetes mellitus type 2 (also known as type 2 diabetes) is a long-term progressive metabolic disorder characterized by high blood sugar, insulin resistance, and reduced insulin production. People with type 2 diabetes represent 90% of the worldwide diabetes population, whereas 10% of this population is diagnosed with type 1 diabetes (a form of diabetes mellitus in which not enough insulin is produced). Being overweight is a condition where the patient’s body mass index (BMI) is greater than 25 (kg/m 2 When considering treatment for type 2 diabetes, it is optimal to address obesity concurrently with diabetes. EndoBarrier ® . The current treatment paradigm for type 2 diabetes is primarily pharmacological, whereby treating clinicians prescribe a treatment regimen of 1–4 concurrent medications that could include insulin for patients with higher levels of blood sugar. Insulin carries a significant risk of increased mortality and directly contributes to weight gain, which in turn leads to higher levels of insulin resistance and diabetes. In other words, the primary drug used to treat severe type 2 diabetes raises risk significantly and increases the downstream progression of the disease by increasing obesity. Fewer than 50% of patients treated pharmacologically for type 2 diabetes are adequately managed, meaning that medication alone does not halt the progressive nature of diabetes for these patients. The current pharmacological treatment algorithms for type 2 diabetes fall short of ideal, creating a large and unfilled treatment gap. Our vision is to make EndoBarrier Since incorporation, the Company has devoted substantially all of its efforts to product commercialization, research and development, business planning, recruiting management and technical staff, acquiring operating assets, and raising capital. The Company currently operates in one reportable business segment. In 2011, the Company began commercial sales of its product, EndoBarrier, which was approved and commercially available in multiple countries outside the U.S. at the time. In the U.S., the Company received approval from the Food and Drug Administration (“FDA”), to commence its pivotal trial of EndoBarrier (the “ENDO Trial”), which the Company began in 2013. The multi-center, randomized, double-blinded study planned to enroll 500 patients with uncontrolled type 2 diabetes and obesity at 25 sites in the U.S. The primary endpoint was improvement in diabetes control as measured by HbA1c levels. In the second half of fiscal year 2015, the Company announced its decision to stop the ENDO Trial. On August 21, 2015, the Company announced that it was reducing headcount by approximately 46% as part of its efforts to restructure its business and expenses in response to stopping the ENDO Trial and to ensure sufficient cash remained available for it to establish new priorities, continue limited market development and research, and to evaluate strategic options. In the second and third quarters of fiscal 2016, the Company took additional actions that it thought necessary to allow the opportunity to evolve its strategic options. These actions resulted in non-recurring charges totaling approximately $1.1 million, including $0.4 million related to restructuring charges in our second quarter, $0.6 million related to employee departures in both our second and third quarters and $0.1 million related to abandonment of our former headquarters in Lexington, MA. In October 2016, the Company received final cancellation notification from the Therapeutic Goods Administration (“TGA”) for the listing of EndoBarrier on the Australian Register of Therapeutic Goods (“ARTG”). In May 2017, the Company received notification from its notified body, SGS United Kingdom Limited (“SGS”), that the CE Mark for EndoBarrier had been suspended pending closure of non-conformances related to its quality management system required under International Organization for Standardization (“ISO”) regulations. On November 10, 2017, the Company received notification that SGS was withdrawing the Certificate of Conformance for EndoBarrier, ending the CE Marking of EndoBarrier in Europe and select Middle East countries. In December 2017, the Company received notification from the Medicines and Healthcare Products Regulatory Agency (“MHRA”) that all EndoBarrier delivery systems (liners) in customers’ inventory need to be returned to the Company. In August 2018, the Company received approval of an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in a pivotal trial evaluating the safety and efficacy of EndoBarrier in the United States pending Institutional Review Board (IRB) approval. From its inception in 2003 to its initial public offering (“IPO”) in 2011, the Company was financed by a series of preferred stock financings In September 2011, the Company completed its initial public offering (“IPO”) of common stock in the form of CHESS Depositary Interests (“CDIs”) in Australia. As a result of the IPO and simultaneous private placement in the U.S., the Company raised a total of approximately $72.5 million in proceeds, net of expenses and repayment of $6.0 million of the Company’s Convertible Term Promissory Notes. Additionally, in July and August 2013, the Company issued CDIs on the Australian Securities Exchange (“ASX”) through a private placement and Share Purchase Plan (“SPP”), which raised a total of approximately $52.5 million, net of expenses. In May 2014, the Company raised an additional total of approximately $30.8 million, net of expenses, when it issued CDIs on the ASX through a private placement. On December 20, 2016, the Company completed a private placement issue of 69,865,000 CDIs (1,397,300 shares) at an issue price of $0.22 per CDI raising approximately $1.0 million, net of issuance costs. In January 2017, the Company completed the issue of 12,481,600 CDI’s (249,632 shares) to eligible investors under a Security Purchase Plan for approximately $0.83 per share (A$0.022 per CDI) resulting in net proceeds after issuance costs of approximately $0.2 million. In June 2017, the Company completed a Convertible Term Promissory Note (the “2017 Note”) financing with its largest shareholder Crystal Amber for a gross amount of $5.0 million that accrues interest at 5% per annum compounded annually. Crystal Amber is deemed a Related Party of the Company due to the size of its ownership position. The Note is due by December 31, 2018 and contains provisions for conversion during the term of the 2017 Note (See Note 10 of the Consolidated Financial Statements for a more complete description of the terms and conditions). In January and March 2018, the Company raised approximately $1.6 million in an offering of its CDIs to sophisticated and professional investors, including certain existing investors, in Australia, the United States and the United Kingdom. In May 2018, the Company completed a Convertible Term Promissory Note (the “2018 Note”) and Warrant (the “2018 Warrant”) financing with its largest shareholder Crystal Amber for a gross amount of $1.75 million that accrues interest at 10% per annum compounded annually. The Note and Warrant financing was approved in a vote of the shareholders of GI Dynamics during the Annual Meeting of Stockholders held on May 24, 2018. The 2018 Note matures and the 2018 Warrant expires on May 30, 2023. Crystal Amber is deemed a Related Party of the Company due to the size of its ownership position. (See Note 10 of the Consolidated Financial Statements for a more complete description of the terms and conditions). In September 2018, the Company received commitments for a private placement of approximately $5 million in an offering of its CDIs to sophisticated and professional investors, including certain existing investors, in Australia, the United States and the United Kingdom. The first tranche of $2.2 million closed and cash was received in September 2018. The second and final tranche of $2.8 million was contingent upon shareholder approval which was received in October 2018. Cash proceeds were received in November 2018. Going Concern As of September 30, 2018, the Company’s primary source of liquidity is its cash and cash equivalents balances. The Company continues to evaluate which markets are appropriate to pursue regulatory approvals, continue pursuing reimbursement, market awareness and general market development and selling efforts. The Company continues to restructure its business and costs, establish new priorities, and evaluate strategic options. As a result, if the Company remains in business, it expects to incur significant operating losses for the next several years. The Company has incurred operating losses since inception and at September 30, 2018 had an accumulated deficit of approximately $265 million, a working capital deficit of approximately $3.9 million, cash used in operating activities of approximately $5.2 million and cash and cash equivalents of approximately $3.1 million. $2.8 million from the second and final tranche of the 2018 private placement was received in November 2018. Cash provided by these activities will be used predominantly to prepare for the Company’s clinical trial, which will result in increased expenses. The Company does not expect its current cash balances will be sufficient to operate beyond the end of the fourth quarter of 2018, as the 2017 Note is payable on December 31, 2018. Both parties are aware that if the Company is required to make this payment on the due date of December 31, 2018, it will be required either to renegotiate the due date of the loan or potentially cease operations. Crystal Amber and the Company are planning to discuss an extension of the due date of the 2017 Note, but there can be no assurance that any extension will occur. If the Company is able to amend the terms of the 2017 Note, it believes its cash and cash equivalents will be sufficient to fund operations into the earlier of the second quarter of 2019 or until the modified due date of the note. The Company will need to raise additional funds through any combination of collaborative arrangements, strategic alliances, and additional equity and debt financings or from other sources. The Company has no guaranteed source of capital that will sustain operations beyond the fourth quarter of 2018, as the 2017 Note is currently payable on December 31, 2018. Crystal Amber and the Company are planning to discuss an amendment to the terms of the 2017 Note, but there can be no guarantee that this will happen. If the Company is able to amend the terms of the 2017 Note, it believes its cash and cash equivalents will be sufficient to fund operations into the earlier of the second quarter of 2019 or until the modified due date of the note. There can be no assurance that other potential financing opportunities will be available on acceptable terms, if at all. As such, if access to capital is not achieved to satisfy cash needs in the near term, the Company’s business, financial condition and results of operations will be materially harmed or the Company may be required to cease operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. The consolidated financial statements as of September 30, 2018 and December 31, 2017 and the three and nine months ended September 30, 2018 and 2017 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Basis of Presentation	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Basis of Presentation	2. Summary of Significant Accounting Policies and Basis of Presentation The accompanying interim consolidated financial statements and related disclosures as of September 30, 2018, and for the three and nine months ended September 30, 2018 and 2017 are unaudited and have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K (“Form 10-K”), filed with the SEC on March 28, 2018. The December 31, 2017 consolidated balance sheet included herein was derived from the audited financial statements as of that date but does not include all disclosures including notes required by GAAP for complete financial statements. Principles of Consolidation The accompanying consolidated financial statements include the accounts of GI Dynamics, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances are eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent assets and liabilities. On an ongoing basis, the Company’s management evaluates its estimates, including those related to revenue recognition, allowance for doubtful accounts, inventory valuation including reserves for excess and obsolete inventory, impairment of long-lived assets, income taxes including the valuation allowance for deferred tax assets, research and development, contingencies, valuation of warrant liabilities, estimates used to assess its ability to continue as a going concern and stock-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. Cash and Cash Equivalents The Company considers all highly liquid investment instruments with an original maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents primarily consist of money market funds and have a carrying amount that approximates fair value. The amount of cash equivalents included in cash and cash equivalents was approximately $3.1 million Inventory The Company states inventory at the lower of first-in, first-out cost or net realizable value. When capitalizing inventory, the Company considers factors such as status of regulatory approval, alternative use of inventory, and anticipated commercial use of the product. At September 30, 2018 and December 31, 2017, the Company had a net inventory balance of $0. Property and Equipment Property and equipment, including leasehold improvements, are recorded at cost and are depreciated when placed in service using the straight-line method based on their estimated useful lives. Included in property and equipment are certain costs of software obtained for internal use. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining lease term. Costs for capital assets not yet placed into service have been capitalized as construction in progress and will be depreciated in accordance with the above guidelines once placed into service. Maintenance and repair costs are expensed as incurred. The Company recorded a loss on disposal of $2 thousand in connection with the expiration of its office lease and the related leasehold improvements on April 13, 2018. Revenue Recognition Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers Revenues include product sales, net of estimated returns. As of January 1, 2018, revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. In most cases, the Company has a single product delivery performance obligation. Product returns are estimated based on historical data and evaluation of current information. From January 1, 2018 to September 30, 2018, the Company did not enter into any revenue contracts with customers and did not recognize or defer any revenue related to new contracts. At September 30, 2018 and December 31, 2017, the Company had deferred revenue of approximately $11 At December 31, 2017, following the notification by MHRA, the Company calculated an estimate for returns, reversed its revenue and recorded an accrued expense estimate of $0.2 million of product return related costs. Shipping and Handling Costs Shipping and handling costs are included in costs of revenue. Research and Development Costs Research and development costs are expensed when incurred. Research and development costs include costs of all basic research activities as well as other research, engineering, and technical effort required to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses. Patent Costs The Company expenses as incurred all costs, including legal expenses, associated with obtaining patents until the patented technology becomes feasible. All costs incurred after the patented technology is feasible will be capitalized as an intangible asset. As of September 30, 2018, and December 31, 2017, no such costs had been capitalized. The Company expensed approximately $0.1 million and $0.3 of patent costs within general and administrative expenses in the consolidated statements of operations for the nine months ended September 30, 2018 and 2017, respectively. Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718, Stock Compensation For awards that vest based on service conditions, the Company uses the straight-line method to allocate compensation expense to reporting periods. The grant date fair value of options granted is calculated using the Black-Scholes option pricing model, which requires the use of subjective assumptions including volatility, expected term and the fair value of the underlying common stock, among others. The Company periodically issues performance-based awards. For these awards, vesting will occur upon the achievement of certain milestones. When achievement of the milestone is deemed probable, the Company expenses the compensation of the respective awards over the implicit service period. Stock awards to non-employees are accounted for in accordance with ASC 505-50, Equity-Based Payments to Non-Employees Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting The stock-based compensation plans provide that grantees may have the right to exercise an option prior to vesting. Shares purchased upon the exercise of unvested options will be subject to the same vesting schedule as the underlying options and are subject to repurchase at the original exercise price by the Company should the grantee discontinue providing services to the Company for any reason, prior to becoming fully vested in such shares. Impairment of Long-Lived Assets The Company regularly reviews the carrying amount of its long-lived assets to determine whether indicators of impairment may exist that warrant adjustments to carrying values or estimated useful lives. If indications of impairment exist, projected future undiscounted cash flows associated with the asset are compared to the carrying amount to determine whether the asset’s value is recoverable. If the carrying value of the asset exceeds such projected undiscounted cash flows, the asset will be written down to its estimated fair value. Loss Contingencies In accordance with ASC 450, Contingencies Income Taxes The Company provides for income taxes under the liability method. The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company’s financial reporting and the tax bases of assets and liabilities measured using the enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to reflect the uncertainty associated with their ultimate realization. The Company accounts for uncertain tax positions recognized in the consolidated financial statements by applying a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Guarantees The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, Guarantees As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. For the nine months ended September 30, 2018, and 2017, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible. As a result, no related reserves have been established. Issuance Costs Related to Equity and Debt The Company allocates issuance costs between the individual freestanding instruments identified on the same basis as proceeds were allocated. Issuance costs associated with the issuance of stock or equity contracts (i.e., equity-classified warrants and convertible preferred stock) are recorded as a charge against the gross proceeds of the offering. Any issuance costs associated with the issuance of liability-classified warrants are expensed as incurred. Issuance costs associated with the issuance of debt (i.e., convertible debt) is recorded as a direct reduction of the carrying amount of the debt liability but limited to the notional value of the debt. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount to interest expense using the effective interest method over the expected term of the notes pursuant to ASC 835, Interest Embedded Conversion Features The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options.” Under the ASC 470-20, an entity must separately account for the liability and equity components of the convertible debt instruments that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer’s economic interest cost. The effect of ASC 470-20 on the accounting for our convertible debt instruments is that the equity component is required to be included in the additional paid-in capital section of stockholders’ equity on the consolidated balance sheets and the value of the equity component is treated as original issue discount for purposes of accounting for the debt component of the notes. As a result, we are required to record non-cash interest expense as a result of the amortization of the discounted carrying value of the convertible debt to their face amount over the term of the convertible debt. We report higher interest expense in our financial results because ASC 470-20 requires interest to include both the current period’s amortization of the debt discount and the instrument’s coupon interest. For conventional convertible debt where the rate of conversion is below market value, the Company records a "beneficial conversion feature" ("BCF") and related debt discount. When the Company records a BCF, the relative fair value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid in capital) and amortized to interest expense over the life of the debt. Subsequent Events The Company evaluates events occurring after the date of its consolidated balance sheet for potential recognition or disclosure in its consolidated financial statements. There have been no subsequent events that occurred through the date the Company issued its consolidated financial statements that require disclosure in or adjustment to its consolidated financial statements. New Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its consolidated financial position or results of operations upon adoption. In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers Revenue Recognition In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory In January 2016, the FASB issued ASU No. 2016-01, " Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force) Statement of Cash Flows In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issue Task Force) In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (ASC 260) Distinguishing Liabilities from Equity (ASC 480) Derivatives and Hedging (ASC 815),”

Net Loss per Common Share

Net Loss per Common Share	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Net Loss per Common Share	3. Net Loss per Common Share Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Potential common stock equivalents are determined using the treasury stock method. For diluted net loss per share purposes, the Company excludes stock options and other stock-based awards, including shares issued as a result of option exercises but which are subject to repurchase by the Company, whose effect would be anti-dilutive from the calculation. During the three and nine months ended September 30, 2018 and 2017, common stock equivalents were excluded from the calculation of diluted net loss per common share, as their effect was anti-dilutive due to the net loss incurred. Therefore, basic and diluted net loss per share was the same in all periods presented. The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding as of September 30, 2018 and 2017, as they would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Warrants to purchase common stock 1,972,976 28,532 1,972,976 28,532 Options to purchase common stock and other stock-based awards 1,545,719 1,504,938 1,545,719 1,504,938 Total 3,518,695 1,533,470 3,518,695 1,533,470

Warrants to Purchase Common Sto

Warrants to Purchase Common Stock and CDIs	9 Months Ended
	Sep. 30, 2018
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Warrants to Purchase Common Stock and CDIs	4. Warrants to Purchase Common Stock and CDIs On May 4, 2016, the Company entered into a consulting agreement pursuant to which a consulting firm provides strategic advisory, finance, accounting, human resources and administrative functions, including chief financial officer services, to the Company. In connection with the consulting agreement, the Company granted the consulting firm a warrant (“Consultant Warrant”) to purchase up to 28,532 shares of the Company’s common stock at an exercise price per share equal to $0.64. The Consultant Warrant vests on a monthly basis over two years and has a term of five years. The Company has reserved 28,532 shares of common stock related to the Consultant Warrant. As of September 30, 2018, the Consultant Warrants had not been exercised. The Company accounts for the Warrants under Accounting Standards Codification 815, Derivatives and Hedging The Consultant Warrant is classified as a liability and as such the fair value of the Warrant must be remeasured at each reporting period. At the time the Warrant was issued, the Company estimated the fair value of the Warrant using the Black-Scholes option pricing model. The Company remeasures the fair value of the Warrant at each reporting period using current assumptions. Changes in value are recorded as other income or expense (Note 5). On May 30, 2018, the Company entered into a Note and Warrant Purchase agreement that included a warrant to purchase 97,222,200 CDIs (representing 1,944,444 shares of common stock). The exercise price is US$0.018 per CDI and the warrants can be exercised with cash or as a net exercise. The warrants are immediately exercisable on issuance and expire on May 30, 2023.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	5. Fair Value of Financial Instruments The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 and indicates the fair value hierarchy of the valuation techniques the Company used to determine such fair value. In general, fair values determined by Level 1 inputs utilize observable inputs such as quoted prices in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, requiring the Company to develop its own assumptions for the asset or liability. The following tables present the assets and liabilities the Company has measured at fair value on a recurring basis (in thousands): Fair Value Measurements at Reporting Date Using Quoted Prices Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs Description September 30, 2018 (Level 1) (Level 2) (Level 3) Assets Money market funds (included in cash and cash equivalents) $ 1,091 $ 1,091 $ — $ — Total assets $ 1,091 $ 1,091 $ — $ — Liabilities Warrant liability $ 16 $ — $ — $ 16 Total liabilities $ 16 $ — $ — $ 16 Fair Value Measurements at Reporting Date Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs Description December 31, 2017 (Level 1) (Level 2) (Level 3) Assets Money market funds (included in cash and cash equivalents) $ 2,584 $ 2,584 $ — $ — Total assets $ 2,584 $ 2,584 $ — $ — Liabilities Warrant liability $ 29 $ — $ — $ 29 Total liabilities $ 29 $ — $ — $ 29 The assumptions used in the Black-Scholes option pricing model to determine the fair value of the Consultant Warrant as of September 30, 2018, and December 31, 2017 were as follows: September 30, December 31, 2018 2017 Exercise price (A$55.00 at the then current exchange rate) $ 0.64 $ 0.64 Fair value of common stock $ 0.72 $ 0.60 Expected volatility 135.0 % 142.6 % Expected term (in years) 2.61 3.34 Risk-free interest rate 2.9 % 2.0 % Expected dividend yield — % — % The following table rolls forward the fair value of the Warrants, where fair value is determined by Level 3 inputs (in thousands): Balance at December 31, 2017 $ 29 Decrease in fair value of warrants upon re-measurement included in other income (expense), net (13 ) Balance at September 30, 2018 $ 16 Cash, cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses, deferred revenue and short-term debt to Crystal Amber Fund Limited, a related party, at September 30, 2018 and December 31, 2017 are carried at amounts that approximate fair value due to their short-term maturities and highly liquid nature of these instruments. The carrying value of the Company’s long-term debt to Crystal Amber Fund Limited, a related party, at September 30, 2018 approximates fair value based on certain industry studies obtained by the Company.

Concentrations of Credit Risk,

Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account	9 Months Ended
	Sep. 30, 2018
Receivables [Abstract]
Concentrations of Credit Risk, Accounts Receivable and Related Valuation Accounts	6. Concentrations of Credit Risk, Accounts Receivable and Related Valuation Accounts Financial instruments that subject the Company to credit risk primarily consists of cash and cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with high quality financial institutions, and consequently, the Company believes that such funds are subject to minimal credit risk. Accounts receivable primarily consists of amounts due from customers, including distributors and health care providers in different countries. In light of the current economic state of many foreign countries, the Company continues to monitor the creditworthiness of its customers. In May 2017, the Company entered into a sales arrangement with certain distributors totaling $517 thousand of EndoBarrier inventory. Due to certain extended right of return periods and payment terms, the Company determined that the revenue and related product costs associated with this transaction should be deferred for accounting purposes. As a result, the Company has recorded an adjustment to accounts receivable of $559 thousand for the unpaid portion of deferred revenue which includes an adjustment of approximately $40 thousand for revaluation of receivables denominated in foreign currency at December 31, 2017. The Company did not have any accounts receivable at September 30, 2018. At December 31, 2017, four health care providers accounted for approximately 100% of the Company’s accounts receivable balance, of approximately equal sums. In certain circumstances, the Company allows customers to return defective or nonconforming products for credit or replacement products. Defective or nonconforming products typically include those products that resulted in an unsuccessful implant procedure. The Company records an estimate for product returns based upon historical trends. The associated reserve for product returns is recorded as a reduction of the Company’s accounts receivable. The following table shows the components of the Company’s accounts receivable at September 30, 2018 and December 31, 2017 (in thousands): September 30, December 31, 2018 2017 Accounts receivable $ — $ 85 Less: allowance for doubtful accounts — (42 ) Less: allowance for sales returns — (3 ) Total $ — $ 40 The following is a rollforward of the Company’s allowance for doubtful accounts (in thousands): Nine Months Ended September 30, 2018 2017 Beginning balance $ 42 $ 16 Net charges to expenses (42 ) 48 Utilization of allowances — (22 ) Ending balance $ — $ 42

Inventory

Inventory	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Inventory	7. Inventory The Company states inventory at the lower of first-in, first-out cost or net realizable value. When capitalizing inventory, the Company considers factors such as status of regulatory approval, alternative use of inventory, and anticipated commercial use of the product. The determination of obsolete or excess inventory requires the Company to estimate the future demand for its products within appropriate time horizons. The estimated future demand is compared to inventory levels to determine the amount, if any, of obsolete and excess inventory. The demand forecast includes the Company’s estimates of market growth and various internal estimates and is based on assumptions that are consistent with the plans and estimates the Company is using to manage its underlying business and short-term manufacturing plans. Forecasting demand for EndoBarrier in a market in which there are few, if any, comparable approved devices and for which reimbursement from third-party payers is limited is challenging. To the extent the Company’s demand forecast is less than its inventory on-hand, the Company could be required to record additional reserves for excess, expired or obsolete inventory in the future. During 2017, the Company charged the remaining balance of its inventory in the normal course of business to cost of sales. As of December 31, 2017, the Company has fully reserved for its inventory on hand and expects to utilize the reserved inventory to meet its future strategic goals. Inventory, net of reserves of approximately $5 million, is $0 at September 30, 2018 and December 31, 2017.

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2018
Property Plant And Equipment [Abstract]
Property and Equipment	8. Property and Equipment Property and equipment consisted of the following (in thousands): September 30, December 31, 2018 2017 Laboratory and manufacturing equipment $ 591 $ 591 Computer equipment and software 1,179 1,179 Office furniture and equipment 183 183 Leasehold improvements — 21 1,953 1,974 Less accumulated depreciation and amortization (1,869 ) (1,877 ) Total $ 84 $ 97 Depreciation and amortization expense of property and equipment totaled approximately $0 and $11 thousand for the three months ended September 30, 2018 and September 30, 2017, respectively and $11 and $46 thousand for the nine months ended September 30, 2018 and 2017, respectively. The Company recorded a loss on disposal of $2 thousand in connection with the expiration of its office lease and the related leasehold improvements on April 13, 2018.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2018
Payables And Accruals [Abstract]
Accrued Expenses	9. Accrued Expenses Accrued expenses consisted of the following (in thousands): September 30, December 31, 2018 2017 Payroll and related liabilities $ 268 $ 181 Professional fees 639 421 Credit refunds 175 279 Interest payable 386 136 Other 48 4 Total $ 1,516 $ 1,021

Related Party Convertible Notes

Related Party Convertible Notes	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Related Party Convertible Notes	10. Related Party Convertible Notes 2017 Convertible Note Financing On June 15, 2017, the Company entered into a Note Purchase Agreement by and between the Company, as borrower, and Crystal Amber Fund Limited, as purchaser (the “Purchaser”). Pursuant to the Note Purchase Agreement, the Company issued and sold to the Purchaser a Senior Secured Convertible Promissory Note in an aggregate original principal amount of $5.0 million (the “2017 Note”). The Purchaser is a related party and is the Company’s largest shareholder. The 2017 Note accrues interest at a rate equal to 5% per annum, compounded annually, other than during the continuance of an event of default, when the 2017 Note accrues interest at a rate of 8% per annum. The entire outstanding principal balance and all unpaid accrued interest thereon is due on the maturity date, December 31, 2018. The 2017 Note is secured by a first priority security interest in substantially all personal property assets of the Company, including intellectual property. The entire outstanding principal balance under the 2017 Note and all unpaid accrued interest thereon is convertible into CHESS Depositary Interests (“CDIs”), each representing 1/50th of a share of the Company’s common stock, (i) at the option of the Purchaser at a conversion price calculated based on the five-day volume weighted average closing price of the Company’s CDIs on the ASX (“Optional Conversion Price”), or (ii) automatically upon the occurrence of an equity financing in which the Company raises at least $10 million (a “Qualified Financing”) at the price per CDI of the CDIs issued and sold in such financing. In the event that the Borrower issues additional CDIs in a subsequent equity financing at a price per CDI that is less than the then-effective optional conversion price (based on the five-day volume weighted average price on the ASX), the Purchaser has a 30-day option to convert at an adjusted conversion price reflecting, on a weighted average basis, the lower price per CDI. The number of CDIs that the Purchaser may acquire upon conversion of the 2017 Note at this adjusted conversion price is limited to the number that maintains the Purchaser’s fully-diluted ownership percentage of the Company at the same level as existed immediately preceding the applicable subsequent equity financing. In addition, upon a change of control of the Company (other than a change of control resulting from a Qualified Financing) in which the Company’s stockholders receive cash consideration, the Company is obligated to prepay all accrued and unpaid interest plus 110% of the remaining outstanding unconverted principal balance. If the consideration received for such change of control is a non-cash consideration, the Purchaser may convert the entire outstanding principal balance under the 2017 Note and all unpaid accrued interest thereon into CDIs at the abovementioned Optional Conversion Price. Other than as described above, the Company may not prepay the 2017 Note without the consent of the Purchaser. The 2017 Note Purchase Agreement contains customary events of default including a failure to perform obligations under the 2017 Note Purchase Agreement, bankruptcy, a decision by the board of directors of the Company to wind up the Company, or if the Company otherwise ceases to carry on its ongoing business operations. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the 2017 Note may be accelerated. The 2017 Note Purchase Agreement and related 2017 Note documents also contain additional representations and warranties, covenants and conditions, in each case customary for transactions of this type. The Company recorded the $5 million 2017 Note, net of debt issuance costs of $115 thousand and will amortize the debt issuance costs over the life of the 2017 Note. For the three and nine months ended September 30, 2018, the Company recognized interest expense of $67 thousand and $191 thousand and amortization of debt issuance costs of $19 thousand and $56 thousand, respectively, related to the 2017 Note. Due to the timing of the finalization of the 2017 Note financing in 2017, the 2017 Note was issued without stockholder approval. As a consequence, while the 2017 Note contains conversion provisions, the Purchaser had, for a period of time, no right to exercise those rights until such rights of exercise were approved by the stockholders of the Company. Stockholder approval of the Purchaser’s right to convert the 2017 Note was obtained at the Company’s Annual Meeting on May 24, 2018. As of the date of this report, the 2017 Note has not been converted by the Purchaser. 2018 Convertible Note and Warrant Financing On May 30, 2018, the Company entered into a Note Purchase Agreement by and between the Company, as borrower, and Crystal Amber Fund Limited, as purchaser (the “Purchaser”). Pursuant to the Note Purchase Agreement, the Company issued and sold to the Purchaser a Senior Unsecured Convertible Promissory Note in an aggregate original principal amount of $1.75 million (the “2018 Note”). The Purchaser is a related party and is the Company’s largest shareholder. The 2018 Note accrues interest at a rate equal to 10% per annum, compounded annually, other than during the continuance of an event of default, when the 2018 Note accrues interest at a rate of 16% per annum. The entire outstanding principal balance and all unpaid accrued interest thereon is due on the maturity date, May 30, 2023. The entire outstanding principal balance under the 2018 Note and all unpaid accrued interest thereon is convertible into CHESS Depositary Interests (“CDIs”), each representing 1/50th of a share of the Company’s common stock, at the option of the Purchaser at a conversion price of $0.018 per CDI. In the event that the Borrower issues additional CDIs in a subsequent equity financing at a price per CDI that is less than $0.018 the conversion price of the 2018 Note will adjust to the lower CDI conversion price. In addition, upon a change of control of the Company, the Purchaser may demand prepayment of accrued and unpaid interest plus 110% of the remaining outstanding unconverted principal balance of the 2018 Note. The 2018 Note contains customary events of default including a failure to perform obligations under the 2018 Note Purchase Agreement, bankruptcy, a decision by the board of directors of the Company to wind up the Company, or if the Company otherwise ceases to carry on its ongoing business operations. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the 2018 Note may be accelerated. The 2018 Note Purchase Agreement and related 2018 Note documents also contain additional representations and warranties, covenants and conditions, in each case customary for transactions of this type. In connection with the issuance of the 2018 Note, the Company also issued to the Purchaser a warrant to purchase 97,222,200 CDIs at an initial exercise price of $0.018 per CDI, subject to adjustment as described in the warrant, which warrant expires on May 30, 2023 (the “2018 Warrant”). The 2018 Warrant may be exercised at any time on a cash or cashless basis. The 2018 Warrant includes a price protection clause. If the Company issues securities in a subsequent financing at a per CDI price of less than $0.018, the exercise price of the 2018 Warrant will be reduced to the lowest such price per CDI (or the equivalent for shares of common stock) at which the newly issued securities were sold. The Company has evaluated the guidance ASC 480-10 Distinguishing Liabilities from Equity, A Contracts in an Entity's Own Equity Debt with Conversion and Other Options The Company recorded the 2018 Note, net of the total debt discount of $1.75 million and will amortize the debt discount over the life of the 2018 Note. For the three and nine months ended September 30, 2018, the Company recognized interest expense of $44 thousand and $58 thousand and amortization of the debt discount of $70 thousand and $95 thousand, respectively. For the three and nine months ended September 30, 2018, the Company recognized interest expense derived from issuance costs of $0 and $85 thousand, respectively.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Lease Commitments In June 2016, the Company entered into a noncancelable agreement to lease approximately 4,200 square feet of office and laboratory space in Boston, Massachusetts. The lease commenced in June 2016 and expired in April 2018. Rent during the term was $11,900 per month. Rent expense on noncancelable operating leases was $0 and $36 thousand for the three months ended September 30, 2018 and 2017, respectively and $37 and $107 thousand for the nine months ended September 30, 2018 and 2017, respectively.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Stockholders' Equity (Deficit)	12. Stockholders’ Equity (Deficit) On May 22, 2017, the Stockholders of the Company approved an increase of its authorized shares of Common Stock from 13,000,000 to 50,000,000 and to eliminate Class B shares of Common Stock of the Company. As of September 30, 2018, the authorized capital stock of the Company consists of 50,500,000 shares, of which 50,000,000 shares are designated as Common Stock and 500,000 shares are designated as Preferred Stock. In 2018, the Company received commitments for two private placements to sophisticated and professional investors in Australia, the United States and the United Kingdom, consisting of U.S. and non-U.S. persons (as defined in Regulation S (“Regulation S”) of the Securities Act of 1933 (the “Securities Act”)) to raise up to approximately $6.61 million (the “2018 Placements”). The first placement (“First Quarter 2018 Placement”) consisted of a total of 406,002,869 fully paid CDIs of the Company (representing 8,120,057 shares of common stock) at an issue price of A$0.035 per CDI. The issue of CDIs under the First Quarter 2018 Placement occurred in two tranches. The first tranche closed on January 22, 2018 (US EST), pursuant to which the Company issued 28,467,063 CDIs (representing 569,341 shares of common stock) resulting in gross proceeds of approximately $781 thousand and related issuance costs of $63 thousand. The closing of the second tranche of the First Quarter 2018 Placement resulted in the raising of $824 thousand and related issuance costs of $39 thousand by the issue of 30,313,556 CDIs (606,271 shares) following stockholder approval granted on February 27, 2018. There were two participants in the First Quarter 2018 Placement second tranche; Crystal Amber Fund, a related party, purchased 27,391,756 CDIs. A Board member of the Company purchased 2,921,800 CDIs. The second placement (“Autumn 2018 Placement”) consisted of a total of 347,222,250 fully paid CDIs of the Company (representing 6,944,445 shares of common stock) at an issue price of A$0.020 per CDI. The investors in the Autumn 2018 Placement included certain existing investors. The issue of these CDIs occurred in two tranches. The first tranche closed on September 20, 2018 (US EST), pursuant to which the Company issued 150,000,000 CDIs (representing 3,000,000 shares of common stock) resulting in gross proceeds of approximately $2.2 million and related issuance costs of $56 thousand. The closing of the second tranche resulted in the raising of $2.8 million by the issue of 197,222,250 CDIs (representing 3,944,445 shares of common stock) following stockholder approval at the adjourned Special Meeting of stockholders on October 29, 2018. There were three participants in the second tranche; Crystal Amber Fund, a related party, purchased 168,194,450 CDIs. Existing investors in the United States and Australia also purchased 23,819,450 and 5,208,350 CDIs, respectively. All second tranche CDIs are expected to be allotted to investors in November 2018..

Stock Plans

Stock Plans	9 Months Ended
	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Plans	13. Stock Plans The Company has two stock-based compensation plans under which incentive stock options, nonqualified stock options, restricted and unrestricted stock awards, and other stock-based awards are available for grant to employees, directors and consultants of the Company. At September 30, 2018, there were 1,545,719 shares available for future grant under the 2011 plan. The 2011 Employee, Director and Consultant Equity Incentive Plan (the “2011 Plan,” together with the 2003 Omnibus Stock Plan, the “Plans”) allows for an annual increase in the number of shares available for issue under the 2011 Plan commencing on the first day of each fiscal year during the period beginning in fiscal year 2012 and ending in fiscal year 2020. The annual increase in the number of shares shall be equal to the lowest of: a. 500,000 shares; b. 4% of the number of common shares outstanding as of such date; and c. an amount determined by the Board of Directors or the Company’s compensation committee. Accordingly, in the first quarter of fiscal 2018, 446,299 options available for future grant were added to the 2011 Plan. Stock-Based Compensation Stock-based compensation is reflected in the consolidated statements of operations as follows for the three and nine months ended September 30, 2018 and 2017 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Research and development $ 1 $ 11 $ 6 $ 24 Sales and marketing 5 38 15 67 General and administrative 16 32 65 71 $ 22 $ 81 $ 86 $ 162 The stock options granted under the Plans generally vest over a four-year period and expire ten years from the date of grant. From time to time, the Company grants stock options to purchase common stock subject to performance-based milestones. The vesting of these stock options will occur upon the achievement of certain milestones. When achievement of the milestone is deemed probable, the Company expenses the compensation of the respective stock option over the implicit service period. In calculating stock-based compensation costs, the Company estimates the fair value of stock options using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model was developed for use in estimating the fair value of short-lived, exchange-traded options that have no vesting restrictions and are fully transferable. Such costs are then recognized over the requisite service period of the awards on a straight-line basis. Determining the fair value of stock-based awards using the Black-Scholes option-pricing model requires the use of highly subjective assumptions, including the expected term of the award and expected stock price volatility. The weighted-average assumptions used to estimate the fair value of employee stock options using the Black-Scholes option-pricing model were as follows for the three and nine months ended September 30, 2018 and 2017: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Expected volatility 120.3 % 88.2 % 120.3 % 87.8 % Expected term (in years) 6.05 6.05 6.05 6.05 Risk-free interest rate 3.0 % 2.1 % 3.0 % 2.1 % Expected dividend yield 0 % 0 % 0 % 0 % Stock Options The following table summarizes share-based activity under the Company’s stock option plans for the nine months ended September 30, 2018: Shares of Common Stock Attributable to Options Weighted- Average Exercise Price Weighted- Average Contractual Life Aggregate Intrinsic Value (in years) (in thousands) Outstanding at December 31, 2017 992,221 $ 10.71 5.72 $ 63 Granted 122,500 $ — $ — Exercised — $ — $ — Cancelled (381,043 ) $ 5.31 $ — Outstanding at September 30, 2018 733,678 $ 4.67 5.96 $ 16 Vested or expected to vest at September 30, 2018 733,678 $ 4.67 5.96 $ 16 Exercisable at September 30, 2018 337,063 $ — — — As of September 30, 2018, there was approximately $299 thousand of unrecognized stock-based compensation related to unvested stock option grants having service-based vesting under the Plans which is expected to be recognized over a weighted-average period of 2.6 years. The intrinsic value in the table above represents the difference between the fair value of the Company’s common stock on the measurement date and the exercise price of the stock option. The stock-based compensation plans provide that grantees may have the right to exercise an option prior to vesting. Shares purchased upon the exercise of unvested options will be subject to the same vesting schedule as the underlying options and are subject to repurchase at the original exercise price by the Company should the grantee discontinue providing services to the Company for any reason, prior to becoming fully vested in such shares. Restricted Stock Units & Performance Stock Units Each restricted stock unit and performance stock unit (“RSU & PSU”) issued under the Company Plans represents a contingent right to receive one share of the Company’s common stock. The RSUs & PSUs outstanding at September 30, 2018 vest upon the achievement of certain product revenue, regulatory and reimbursement milestones. There is no consideration payable on the vesting of RSUs & PSUs issued. Upon vesting, RSUs and PSUs are exercised automatically and settled in shares of the Company’s common stock. The following table summarizes information related to RSU & PSU activity for the nine months ended September 30, 2018: Number of Units Weighted- Average Contractual Life Aggregate Intrinsic Value (in years) (in thousands) Outstanding at December 31, 2017 392,659 8.27 $ 429 Granted — Exercised — Cancelled (142,659 ) — — Outstanding at September 30, 2018 250,000 7.48 $ 208 The aggregate intrinsic value at September 30, 2018 and December 31, 2017 noted in the table above represents the closing price of the Company’s common stock multiplied by the number of RSUs and PSUs outstanding. The fair value of each RSU and PSU award equals the closing price of the Company’s common stock on the date of grant At September 30, 2018, all RSUs and PSUs outstanding are subject to performance-based vesting criteria as described in the applicable award agreement. For these awards, vesting will occur upon the achievement of certain product revenue, regulatory and reimbursement milestones. When achievement of the milestone is deemed probable, the Company expenses the compensation of the respective stock award over the implicit service period. At September 30, 2018 and 2017, no RSUs and PSUs that have performance-based vesting criteria are considered probable of achievement. For the three and nine months ended September 30, 2018 and 2017, the Company did not recognize any stock-based compensation for RSUs and PSUs subject to performance-based vesting criteria. As of September 30, 2018, there remains approximately $150 thousand of unrecognized stock-based compensation.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Segment Reporting	14. Segment Reporting Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company’s chief operating decision-maker in deciding how to allocate resources and in assessing performance. The Company has one reportable segment which designs, develops, manufactures and markets medical devices for non-surgical approaches to treating type 2 diabetes and obesity. Geographic Reporting All the Company’s revenue is attributable to customers outside the U.S. The Company is dependent on favorable economic and regulatory environments for its products. Products were sold to customers located in Europe and the Middle East and sales were attributed to a country or region based on the location of the customer to whom the products were sold. At September 30, 2018, long-lived assets, comprised of property and equipment, of approximately $0.1 million are all held in the U.S. Product sales by geographic location for the three and nine months ended September 30, 2018 and 2017 are listed in the table below (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Europe $ — $ 23 $ — $ 155 Middle East — - — 18 Total $ — $ 23 $ — $ 173 The Company did not have revenue for the three and nine months ended September 30, 2018. Germany was a significant component of revenue in Europe for the three and nine months ended September 30, 2017. Major Customers The Company did not recognize any revenue for the three and nine months ended September 30, 2018. For the three months ended September 30, 2017, the Company recognized as revenue a reversal of prior rebate accruals of approximately $27 thousand originally granted to health care providers which was deemed to no longer be required, in addition the Company deferred a previously recognized sale. For the nine months ended September 30, 2017, two customers accounted for 21% and 15% of the Company’s revenue.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of GI Dynamics, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances are eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent assets and liabilities. On an ongoing basis, the Company’s management evaluates its estimates, including those related to revenue recognition, allowance for doubtful accounts, inventory valuation including reserves for excess and obsolete inventory, impairment of long-lived assets, income taxes including the valuation allowance for deferred tax assets, research and development, contingencies, valuation of warrant liabilities, estimates used to assess its ability to continue as a going concern and stock-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investment instruments with an original maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents primarily consist of money market funds and have a carrying amount that approximates fair value. The amount of cash equivalents included in cash and cash equivalents was approximately $3.1 million
Inventory	Inventory The Company states inventory at the lower of first-in, first-out cost or net realizable value. When capitalizing inventory, the Company considers factors such as status of regulatory approval, alternative use of inventory, and anticipated commercial use of the product. At September 30, 2018 and December 31, 2017, the Company had a net inventory balance of $0.
Property and Equipment	Property and Equipment Property and equipment, including leasehold improvements, are recorded at cost and are depreciated when placed in service using the straight-line method based on their estimated useful lives. Included in property and equipment are certain costs of software obtained for internal use. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining lease term. Costs for capital assets not yet placed into service have been capitalized as construction in progress and will be depreciated in accordance with the above guidelines once placed into service. Maintenance and repair costs are expensed as incurred. The Company recorded a loss on disposal of $2 thousand in connection with the expiration of its office lease and the related leasehold improvements on April 13, 2018.
Revenue Recognition	Revenue Recognition Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers Revenues include product sales, net of estimated returns. As of January 1, 2018, revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. In most cases, the Company has a single product delivery performance obligation. Product returns are estimated based on historical data and evaluation of current information. From January 1, 2018 to September 30, 2018, the Company did not enter into any revenue contracts with customers and did not recognize or defer any revenue related to new contracts. At September 30, 2018 and December 31, 2017, the Company had deferred revenue of approximately $11 At December 31, 2017, following the notification by MHRA, the Company calculated an estimate for returns, reversed its revenue and recorded an accrued expense estimate of $0.2 million of product return related costs.
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling costs are included in costs of revenue.
Research and Development Costs	Research and Development Costs Research and development costs are expensed when incurred. Research and development costs include costs of all basic research activities as well as other research, engineering, and technical effort required to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses.
Patent Costs	Patent Costs The Company expenses as incurred all costs, including legal expenses, associated with obtaining patents until the patented technology becomes feasible. All costs incurred after the patented technology is feasible will be capitalized as an intangible asset. As of September 30, 2018, and December 31, 2017, no such costs had been capitalized. The Company expensed approximately $0.1 million and $0.3 of patent costs within general and administrative expenses in the consolidated statements of operations for the nine months ended September 30, 2018 and 2017, respectively.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718, Stock Compensation For awards that vest based on service conditions, the Company uses the straight-line method to allocate compensation expense to reporting periods. The grant date fair value of options granted is calculated using the Black-Scholes option pricing model, which requires the use of subjective assumptions including volatility, expected term and the fair value of the underlying common stock, among others. The Company periodically issues performance-based awards. For these awards, vesting will occur upon the achievement of certain milestones. When achievement of the milestone is deemed probable, the Company expenses the compensation of the respective awards over the implicit service period. Stock awards to non-employees are accounted for in accordance with ASC 505-50, Equity-Based Payments to Non-Employees Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting The stock-based compensation plans provide that grantees may have the right to exercise an option prior to vesting. Shares purchased upon the exercise of unvested options will be subject to the same vesting schedule as the underlying options and are subject to repurchase at the original exercise price by the Company should the grantee discontinue providing services to the Company for any reason, prior to becoming fully vested in such shares.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company regularly reviews the carrying amount of its long-lived assets to determine whether indicators of impairment may exist that warrant adjustments to carrying values or estimated useful lives. If indications of impairment exist, projected future undiscounted cash flows associated with the asset are compared to the carrying amount to determine whether the asset’s value is recoverable. If the carrying value of the asset exceeds such projected undiscounted cash flows, the asset will be written down to its estimated fair value.
Loss Contingencies	Loss Contingencies In accordance with ASC 450, Contingencies
Income Taxes	Income Taxes The Company provides for income taxes under the liability method. The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company’s financial reporting and the tax bases of assets and liabilities measured using the enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to reflect the uncertainty associated with their ultimate realization. The Company accounts for uncertain tax positions recognized in the consolidated financial statements by applying a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
Guarantees	Guarantees The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, Guarantees As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. For the nine months ended September 30, 2018, and 2017, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible. As a result, no related reserves have been established.
Issuance Costs Related to Equity and Debt	Issuance Costs Related to Equity and Debt The Company allocates issuance costs between the individual freestanding instruments identified on the same basis as proceeds were allocated. Issuance costs associated with the issuance of stock or equity contracts (i.e., equity-classified warrants and convertible preferred stock) are recorded as a charge against the gross proceeds of the offering. Any issuance costs associated with the issuance of liability-classified warrants are expensed as incurred. Issuance costs associated with the issuance of debt (i.e., convertible debt) is recorded as a direct reduction of the carrying amount of the debt liability but limited to the notional value of the debt. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount to interest expense using the effective interest method over the expected term of the notes pursuant to ASC 835, Interest
Embedded Conversion Features	Embedded Conversion Features The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options.” Under the ASC 470-20, an entity must separately account for the liability and equity components of the convertible debt instruments that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer’s economic interest cost. The effect of ASC 470-20 on the accounting for our convertible debt instruments is that the equity component is required to be included in the additional paid-in capital section of stockholders’ equity on the consolidated balance sheets and the value of the equity component is treated as original issue discount for purposes of accounting for the debt component of the notes. As a result, we are required to record non-cash interest expense as a result of the amortization of the discounted carrying value of the convertible debt to their face amount over the term of the convertible debt. We report higher interest expense in our financial results because ASC 470-20 requires interest to include both the current period’s amortization of the debt discount and the instrument’s coupon interest. For conventional convertible debt where the rate of conversion is below market value, the Company records a "beneficial conversion feature" ("BCF") and related debt discount. When the Company records a BCF, the relative fair value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid in capital) and amortized to interest expense over the life of the debt.
Subsequent Events	Subsequent Events The Company evaluates events occurring after the date of its consolidated balance sheet for potential recognition or disclosure in its consolidated financial statements. There have been no subsequent events that occurred through the date the Company issued its consolidated financial statements that require disclosure in or adjustment to its consolidated financial statements.
New Accounting Pronouncements	New Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its consolidated financial position or results of operations upon adoption. In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers Revenue Recognition In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory In January 2016, the FASB issued ASU No. 2016-01, " Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force) Statement of Cash Flows In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issue Task Force) In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (ASC 260) Distinguishing Liabilities from Equity (ASC 480) Derivatives and Hedging (ASC 815),”

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Potentially Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares	The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding as of September 30, 2018 and 2017, as they would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Warrants to purchase common stock 1,972,976 28,532 1,972,976 28,532 Options to purchase common stock and other stock-based awards 1,545,719 1,504,938 1,545,719 1,504,938 Total 3,518,695 1,533,470 3,518,695 1,533,470

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value of Assets and Liabilities Measured on Recurring Basis	The following tables present the assets and liabilities the Company has measured at fair value on a recurring basis (in thousands): Fair Value Measurements at Reporting Date Using Quoted Prices Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs Description September 30, 2018 (Level 1) (Level 2) (Level 3) Assets Money market funds (included in cash and cash equivalents) $ 1,091 $ 1,091 $ — $ — Total assets $ 1,091 $ 1,091 $ — $ — Liabilities Warrant liability $ 16 $ — $ — $ 16 Total liabilities $ 16 $ — $ — $ 16 Fair Value Measurements at Reporting Date Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs Description December 31, 2017 (Level 1) (Level 2) (Level 3) Assets Money market funds (included in cash and cash equivalents) $ 2,584 $ 2,584 $ — $ — Total assets $ 2,584 $ 2,584 $ — $ — Liabilities Warrant liability $ 29 $ — $ — $ 29 Total liabilities $ 29 $ — $ — $ 29
Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Common Stock Warrants	The assumptions used in the Black-Scholes option pricing model to determine the fair value of the Consultant Warrant as of September 30, 2018, and December 31, 2017 were as follows: September 30, December 31, 2018 2017 Exercise price (A$55.00 at the then current exchange rate) $ 0.64 $ 0.64 Fair value of common stock $ 0.72 $ 0.60 Expected volatility 135.0 % 142.6 % Expected term (in years) 2.61 3.34 Risk-free interest rate 2.9 % 2.0 % Expected dividend yield — % — %
Rollforward of Fair Value of Warrants	The following table rolls forward the fair value of the Warrants, where fair value is determined by Level 3 inputs (in thousands): Balance at December 31, 2017 $ 29 Decrease in fair value of warrants upon re-measurement included in other income (expense), net (13 ) Balance at September 30, 2018 $ 16

Concentrations of Credit Risk_2

Concentrations of Credit Risk, Accounts Receivable and Related Valuation Accounts (Tables)	9 Months Ended
	Sep. 30, 2018
Receivables [Abstract]
Components of Company's Accounts Receivable	The following table shows the components of the Company’s accounts receivable at September 30, 2018 and December 31, 2017 (in thousands): September 30, December 31, 2018 2017 Accounts receivable $ — $ 85 Less: allowance for doubtful accounts — (42 ) Less: allowance for sales returns — (3 ) Total $ — $ 40
Rollforward of Allowance for Doubtful Accounts	The following is a rollforward of the Company’s allowance for doubtful accounts (in thousands): Nine Months Ended September 30, 2018 2017 Beginning balance $ 42 $ 16 Net charges to expenses (42 ) 48 Utilization of allowances — (22 ) Ending balance $ — $ 42

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2018
Property Plant And Equipment [Abstract]
Property and Equipment	Property and equipment consisted of the following (in thousands): September 30, December 31, 2018 2017 Laboratory and manufacturing equipment $ 591 $ 591 Computer equipment and software 1,179 1,179 Office furniture and equipment 183 183 Leasehold improvements — 21 1,953 1,974 Less accumulated depreciation and amortization (1,869 ) (1,877 ) Total $ 84 $ 97

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Payables And Accruals [Abstract]
Accrued Expenses	Accrued expenses consisted of the following (in thousands): September 30, December 31, 2018 2017 Payroll and related liabilities $ 268 $ 181 Professional fees 639 421 Credit refunds 175 279 Interest payable 386 136 Other 48 4 Total $ 1,516 $ 1,021

Stock Plans (Tables)

Stock Plans (Tables)	9 Months Ended
	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	Stock-based compensation is reflected in the consolidated statements of operations as follows for the three and nine months ended September 30, 2018 and 2017 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Research and development $ 1 $ 11 $ 6 $ 24 Sales and marketing 5 38 15 67 General and administrative 16 32 65 71 $ 22 $ 81 $ 86 $ 162
Weighted-average Assumptions used to Estimate Fair Value of Stock Options	The weighted-average assumptions used to estimate the fair value of employee stock options using the Black-Scholes option-pricing model were as follows for the three and nine months ended September 30, 2018 and 2017: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Expected volatility 120.3 % 88.2 % 120.3 % 87.8 % Expected term (in years) 6.05 6.05 6.05 6.05 Risk-free interest rate 3.0 % 2.1 % 3.0 % 2.1 % Expected dividend yield 0 % 0 % 0 % 0 %
Share-Based Activity	The following table summarizes share-based activity under the Company’s stock option plans for the nine months ended September 30, 2018: Shares of Common Stock Attributable to Options Weighted- Average Exercise Price Weighted- Average Contractual Life Aggregate Intrinsic Value (in years) (in thousands) Outstanding at December 31, 2017 992,221 $ 10.71 5.72 $ 63 Granted 122,500 $ — $ — Exercised — $ — $ — Cancelled (381,043 ) $ 5.31 $ — Outstanding at September 30, 2018 733,678 $ 4.67 5.96 $ 16 Vested or expected to vest at September 30, 2018 733,678 $ 4.67 5.96 $ 16 Exercisable at September 30, 2018 337,063 $ — — —
Restricted Stock Units and Performance Stock Units Activity	The following table summarizes information related to RSU & PSU activity for the nine months ended September 30, 2018: Number of Units Weighted- Average Contractual Life Aggregate Intrinsic Value (in years) (in thousands) Outstanding at December 31, 2017 392,659 8.27 $ 429 Granted — Exercised — Cancelled (142,659 ) — — Outstanding at September 30, 2018 250,000 7.48 $ 208

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Product Sales by Geographic Location	Product sales by geographic location for the three and nine months ended September 30, 2018 and 2017 are listed in the table below (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Europe $ — $ 23 $ — $ 155 Middle East — - — 18 Total $ — $ 23 $ — $ 173

Nature of Business - Additional

Nature of Business - Additional Information (Detail) $ / shares in Units, $ in Thousands

Dec. 20, 2016USD ($)$ / sharesshares

Aug. 21, 2015

Nov. 30, 2018USD ($)

Sep. 30, 2018USD ($)

May 30, 2018USD ($)

Mar. 31, 2018USD ($)

Jan. 31, 2018USD ($)

Jun. 30, 2017USD ($)

Jan. 31, 2017USD ($)$ / sharesshares

May 31, 2014USD ($)

Sep. 30, 2011USD ($)

Aug. 31, 2013USD ($)

Jun. 30, 2016USD ($)

Sep. 30, 2016USD ($)

Sep. 30, 2018USD ($)SegmentPatientSite

Sep. 30, 2017USD ($)

Dec. 31, 2018USD ($)

Dec. 31, 2017USD ($)

Jan. 31, 2017$ / shares

Nature Of Operations [Line Items]

Number of reportable segments | Segment

1

Number of patients to enroll under double-blinded study plan with uncontrolled type 2 diabetes and obesity | Patient

500

Number of sites consider for trial of EndoBarrier Therapy | Site

25

Percentage of reducing headcount

46.00%

Non-recurring charges

$ 1,100

Issuance of shares, value

$ 1,600

$ 1,600

$ 30,800

$ 72,500

$ 52,500

Repayment of convertible term promissory notes

$ 6,000

$ 214

Common stock issued, price per share | (per share)

$ 0.83

$ 0.022

Private placement amount received

$ 1,000

Proceeds from issuance of common stock

$ 200

$ 3,607

198

Accumulated deficit

$ (264,745)

(264,745)

$ (259,121)

Working capital deficit

(3,900)

(3,900)

Cash used in operating activities

(5,202)

$ (7,647)

Cash and cash equivalents

3,104

$ 3,104

$ 3,034

Tranche One

Nature Of Operations [Line Items]

Private placement amount received

2,200

Private Placement

Nature Of Operations [Line Items]

Issuance of shares, value

$ 5,000

Scenario, Forecast | Tranche Two

Nature Of Operations [Line Items]

Private placement amount received

$ 2,800

Scenario, Forecast | Private Placement

Nature Of Operations [Line Items]

Private placement amount received

$ 6,610

2017 Senior Secured Convertible Promissory Note

Nature Of Operations [Line Items]

Debt principal amount

$ 5,000

Interest rate during period

5.00%

Maturity Date

Dec. 31, 2018

2018 Senior Secured Convertible Promissory Note and Warrant

Nature Of Operations [Line Items]

Debt principal amount

$ 1,750

Interest rate during period

10.00%

Maturity Date

May 30, 2023

Common stock

Nature Of Operations [Line Items]

Stock issued, shares | shares

1,397,300

249,632

CHESS Depositary Interests

Nature Of Operations [Line Items]

Stock issued, shares | shares

69,865,000

12,481,600

Common stock issued, price per share | $ / shares

$ 0.22

Restructuring Charges

Nature Of Operations [Line Items]

Non-recurring charges

$ 400

Employee Severance

Nature Of Operations [Line Items]

Non-recurring charges

600

Facility Closing

Nature Of Operations [Line Items]

Non-recurring charges

$ 100

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Basis of Presentations - Additional Information (Detail) - USD ($)	Apr. 13, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jan. 01, 2018	Dec. 31, 2017	Jan. 01, 2017
Summary Of Significant Accounting Policies [Line Items]
Inventory, net		$ 0		$ 0			$ 0
Loss on disposal of leasehold improvements	$ 2,000			2,000
Contract with customer, liability, revenue recognized				0
Deferred revenue		11,000		11,000			11,000
Estimated accrued expense for product return related costs							200,000
General and administrative		1,338,000	$ 1,095,000	3,378,000	$ 3,624,000
Accounting Standards Update 2016-09
Summary Of Significant Accounting Policies [Line Items]
Decrease in accumulated deficit						$ 28,000		$ 28,000
Patents
Summary Of Significant Accounting Policies [Line Items]
General and administrative				100,000	$ 300,000
Cash and Cash Equivalents
Summary Of Significant Accounting Policies [Line Items]
Cash equivalents		$ 3,100,000		$ 3,100,000			$ 3,000,000

Potentially Dilutive Securities

Potentially Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	3,518,695	1,533,470	3,518,695	1,533,470
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	1,972,976	28,532	1,972,976	28,532
Options to purchase common stock and other stock-based awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	1,545,719	1,504,938	1,545,719	1,504,938

Warrants to Purchase Common S_2

Warrants to Purchase Common Stock and CDIs - Additional Information (Detail) - $ / shares	May 04, 2016	Sep. 30, 2018	May 30, 2018
2018 Senior Secured Convertible Promissory Note and Warrant
Class of Warrant or Right [Line Items]
Warrant expiration date			May 30, 2023
2018 Senior Secured Convertible Promissory Note and Warrant | CHESS Depositary Interests
Class of Warrant or Right [Line Items]
Common stock warrants, shares issued			97,222,200
Common stock warrant, exercise price			$ 0.018
Common stock | 2018 Senior Secured Convertible Promissory Note and Warrant
Class of Warrant or Right [Line Items]
Common stock warrants, shares issued			1,944,444
Consulting Agreement | Consultant Warrant
Class of Warrant or Right [Line Items]
Common stock warrants, shares issued	28,532
Common stock warrant, exercise price	$ 0.64
Vesting period of warrants	2 years
Contractual life of warrants	5 years
Common stock warrant, share reserved	28,532
Common stock warrant, shares exercised		0

Fair Value of Assets and Liabil

Fair Value of Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 16	$ 29
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	1,091	2,584
Warrant liability	16	29
Total liabilities	16	29
Fair Value, Measurements, Recurring | Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	1,091	2,584
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	1,091	2,584
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	1,091	2,584
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	16	29
Total liabilities	$ 16	$ 29

Assumptions Used in the Black-S

Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Common Stock Warrants (Detail)	Sep. 30, 2018$ / shares$ / shares	Dec. 31, 2017$ / shares$ / shares
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value of common stock	$ 0.72	$ 0.60
Exercise Price
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Valuation assumptions measurement input	55	55
Expected Volatility
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Valuation assumptions measurement input	135	142.6
Expected Term
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Valuation assumptions expected term	2 years 7 months 9 days	3 years 4 months 2 days
Risk-free Interest Rate
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Valuation assumptions measurement input	2.9	2
Expected Dividend Yield
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Valuation assumptions measurement input	0	0

Assumptions Used in the Black_2

Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Common Stock Warrants (Parenthetical) (Detail)	Sep. 30, 2018$ / shares	Sep. 30, 2018$ / shares	Dec. 31, 2017$ / shares	Dec. 31, 2017$ / shares
Exercise Price
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Valuation assumptions measurement input	0.64	55	0.64	55

Rollforward of Fair Value of Wa

Rollforward of Fair Value of Warrants (Detail) - Warrant $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 29
Decrease in fair value of warrants upon re-measurement included in other income (expense), net	(13)
Ending balance	$ 16

Concentrations of Credit Risk_3

Concentrations of Credit Risk, Accounts Receivable and Related Valuation Accounts - Additional Information (Detail)	1 Months Ended	9 Months Ended		12 Months Ended
	May 31, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)Customer
Accounts Notes And Loans Receivable [Line Items]
Adjustment to account receivable		$ (40,000)	$ 11,000
Accounts receivable		$ 0		$ 40,000
Accounts Receivable | Credit Concentration Risk | Four Health Care Providers
Accounts Notes And Loans Receivable [Line Items]
Number of customers | Customer				4
Concentration risk percentage				100.00%
Sales Arrangement
Accounts Notes And Loans Receivable [Line Items]
Sales arrangement entered	$ 517,000
Adjustment to account receivable				$ 559,000
Sales Arrangement | Foreign Currency
Accounts Notes And Loans Receivable [Line Items]
Adjustment to account receivable				$ 40,000

Components of Company's Account

Components of Company's Accounts Receivable (Detail) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accounts Notes Loans And Financing Receivable Gross Allowance And Net [Abstract]
Accounts receivable		$ 85,000
Less: allowance for doubtful accounts		(42,000)
Less: allowance for sales returns		(3,000)
Total	$ 0	$ 40,000

Rollforward of Allowance for Do

Rollforward of Allowance for Doubtful Accounts (Detail) - Allowance for Doubtful Accounts - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	$ 42	$ 16
Net charges to expenses	$ (42)	48
Utilization of allowances		(22)
Ending balance		$ 42

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory reserve	$ 5,000,000	$ 5,000,000
Inventory, net of reserves	$ 0	$ 0

Property and Equipment (Detail)

Property and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Property Plant And Equipment [Line Items]
Property Plant and equipment gross	$ 1,953	$ 1,974
Less accumulated depreciation and amortization	(1,869)	(1,877)
Total	84	97
Laboratory and manufacturing equipment
Property Plant And Equipment [Line Items]
Property Plant and equipment gross	591	591
Computer equipment and software
Property Plant And Equipment [Line Items]
Property Plant and equipment gross	1,179	1,179
Office furniture and equipment
Property Plant And Equipment [Line Items]
Property Plant and equipment gross	$ 183	183
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property Plant and equipment gross		$ 21

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	Apr. 13, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Property Plant And Equipment [Abstract]
Depreciation and amortization expense		$ 0	$ 11	$ 11	$ 46
Loss on disposal of leasehold improvements	$ 2			$ 2

Accrued Expenses (Detail)

Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Payables And Accruals [Abstract]
Payroll and related liabilities	$ 268	$ 181
Professional fees	639	421
Credit refunds	175	279
Interest payable	386	136
Other	48	4
Total	$ 1,516	$ 1,021

Related Party Convertible Not_2

Related Party Convertible Notes - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	May 30, 2018	Jun. 15, 2017
Debt Instrument [Line Items]
Amortization of the issuance costs		$ 141	$ 25
Debt instrument, convertible, beneficial conversion feature		1,007
2018 Warrant
Debt Instrument [Line Items]
Estimated fair value of warrant	$ 743	$ 743
2018 Senior Unsecured Convertible Promissory Note
Debt Instrument [Line Items]
Debt principal amount				$ 1,750
Interest rate during period		10.00%
Interest rate during default	16.00%	16.00%
Maturity Date		May 30, 2023
Interest expense	$ 44	$ 58
Debt instrument, convertible, beneficial conversion feature		$ 1,200
Debt instrument, effective interest rate	26.40%	26.40%
Amortization of debt discount	$ 70	$ 95
Interest expense derived from issuance costs	$ 0	85
2018 Senior Unsecured Convertible Promissory Note and Warrant
Debt Instrument [Line Items]
Debt instrument, convertible, beneficial conversion feature		$ 1,000
Chess Deposit Interest | 2018 Warrant
Debt Instrument [Line Items]
Warrant to purchase CDIs				97,222,200
Warrant initial exercise price per CDI				$ 0.018
Warrant expiration date				May 30, 2023
Chess Deposit Interest | 2018 Senior Unsecured Convertible Promissory Note
Debt Instrument [Line Items]
Debt instrument conversion ratio		0.02
Debt instrument conversion description		The entire outstanding principal balance under the 2018 Note and all unpaid accrued interest thereon is convertible into CHESS Depositary Interests (“CDIs”), each representing 1/50th of a share of the Company’s common stock, at the option of the Purchaser at a conversion price of $0.018 per CDI. In the event that the Borrower issues additional CDIs in a subsequent equity financing at a price per CDI that is less than $0.018 the conversion price of the 2018 Note will adjust to the lower CDI conversion price. In addition, upon a change of control of the Company, the Purchaser may demand prepayment of accrued and unpaid interest plus 110% of the remaining outstanding unconverted principal balance of the 2018 Note.
Debt instrument conversion price per CDI	$ 0.018	$ 0.018
Percentage of remaining outstanding unconverted principal payment obligation upon change of control	110.00%	110.00%
2017 Senior Secured Convertible Promissory Note
Debt Instrument [Line Items]
Debt principal amount					$ 5,000
Interest rate during period		5.00%
Interest rate during default	8.00%	8.00%
Maturity Date		Dec. 31, 2018
Debt issuance costs					$ 115
Interest expense	$ 67	$ 191
Amortization of the issuance costs	$ 19	56
2017 Senior Secured Convertible Promissory Note | Chess Deposit Interest
Debt Instrument [Line Items]
Qualified financing least amount raised		$ 10,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2016USD ($)ft²	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)
Loss Contingencies [Line Items]
Rentable area of leased premises | ft²	4,200
Lease commenced date	2016-06
Lease expiration date	2018-04
Rent expense	$ 11,900	$ 0	$ 36,000	$ 37,000	$ 107,000
WeWork Location Boston | Massachusetts
Loss Contingencies [Line Items]
Rent expense		$ 21,000		$ 21,000
Lease term		6 months		6 months

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) - Additional Information (Detail) $ / shares in Units, $ in Thousands

Oct. 29, 2018USD ($)shares

Sep. 20, 2018USD ($)shares

Feb. 27, 2018USD ($)shares

Jan. 22, 2018USD ($)shares

Dec. 20, 2016USD ($)$ / sharesshares

Nov. 30, 2018USD ($)$ / shares

Sep. 30, 2018USD ($)shares

Jan. 31, 2017$ / sharesshares

Nov. 30, 2018$ / sharesshares

Mar. 31, 2018$ / sharesshares

Dec. 31, 2018USD ($)PrivatePlacement

Dec. 31, 2017shares

May 22, 2017shares

Jan. 31, 2017$ / shares

Dec. 31, 2016shares

Class of Stock [Line Items]

Common stock, shares authorized

50,000,000

50,000,000

50,000,000

13,000,000

Capital stock, shares authorized

50,500,000

Preferred stock, shares authorized

500,000

500,000

Common stock issued, price per share | (per share)

$ 0.83

$ 0.022

Private placement amount received | $

$ 1,000

Common stock

Class of Stock [Line Items]

Stock issued, shares

1,397,300

249,632

CHESS Depositary Interests

Class of Stock [Line Items]

Stock issued, shares

69,865,000

12,481,600

Common stock issued, price per share | $ / shares

$ 0.22

Tranche One

Class of Stock [Line Items]

Private placement amount received | $

$ 2,200

Tranche Two | Scenario, Forecast

Class of Stock [Line Items]

Private placement amount received | $

$ 2,800

First Quarter 2018 Placement | Common stock

Class of Stock [Line Items]

Stock issued, shares

8,120,057

First Quarter 2018 Placement | CHESS Depositary Interests

Class of Stock [Line Items]

Stock issued, shares

406,002,869

Common stock issued, price per share | $ / shares

$ 0.035

First Quarter 2018 Placement | Tranche One

Class of Stock [Line Items]

Private placement amount received | $

$ 781

Stock issuance costs | $

$ 63

First Quarter 2018 Placement | Tranche One | Common stock

Class of Stock [Line Items]

Stock issued, shares

569,341

First Quarter 2018 Placement | Tranche One | CHESS Depositary Interests

Class of Stock [Line Items]

Stock issued, shares

28,467,063

First Quarter 2018 Placement | Tranche Two

Class of Stock [Line Items]

Private placement amount received | $

$ 824

Stock issuance costs | $

$ 39

First Quarter 2018 Placement | Tranche Two | Common stock

Class of Stock [Line Items]

Stock issued, shares

606,271

First Quarter 2018 Placement | Tranche Two | CHESS Depositary Interests

Class of Stock [Line Items]

Stock issued, shares

30,313,556

First Quarter 2018 Placement | Tranche Two | CHESS Depositary Interests | Board Member

Class of Stock [Line Items]

Stock issued, shares

2,921,800

First Quarter 2018 Placement | Tranche Two | CHESS Depositary Interests | Crystal Amber Fund

Class of Stock [Line Items]

Stock issued, shares

27,391,756

Private Placement | Scenario, Forecast

Class of Stock [Line Items]

Private placement amount received | $

$ 6,610

Number of private placements | PrivatePlacement

2

Autumn 2018 Placement | Common stock | Scenario, Forecast

Class of Stock [Line Items]

Stock issued, shares

6,944,445

Autumn 2018 Placement | CHESS Depositary Interests | Scenario, Forecast

Class of Stock [Line Items]

Stock issued, shares

347,222,250

Autumn 2018 Placement | CHESS Depositary Interests | Existing Investors | Scenario, Forecast

Class of Stock [Line Items]

Common stock issued, price per share | $ / shares

$ 0.020

$ 0.020

Autumn 2018 Placement | Tranche One

Class of Stock [Line Items]

Private placement amount received | $

$ 2,200

Stock issuance costs | $

$ 56

Autumn 2018 Placement | Tranche One | Common stock

Class of Stock [Line Items]

Stock issued, shares

3,000,000

Autumn 2018 Placement | Tranche One | CHESS Depositary Interests

Class of Stock [Line Items]

Stock issued, shares

150,000,000

Autumn 2018 Placement | Tranche Two

Class of Stock [Line Items]

Private placement amount received | $

$ 2,800

Autumn 2018 Placement | Tranche Two | Common stock

Class of Stock [Line Items]

Stock issued, shares

3,944,445

Autumn 2018 Placement | Tranche Two | CHESS Depositary Interests

Class of Stock [Line Items]

Stock issued, shares

197,222,250

Autumn 2018 Placement | Tranche Two | CHESS Depositary Interests | Existing Investors | United States | Subsequent Event

Class of Stock [Line Items]

Stock issued, shares

23,819,450

Autumn 2018 Placement | Tranche Two | CHESS Depositary Interests | Existing Investors | Australia | Subsequent Event

Class of Stock [Line Items]

Stock issued, shares

5,208,350

Autumn 2018 Placement | Tranche Two | CHESS Depositary Interests | Crystal Amber Fund | Subsequent Event

Class of Stock [Line Items]

Stock issued, shares

168,194,450

Stock Plans - Additional Inform

Stock Plans - Additional Information (Detail)	3 Months Ended			9 Months Ended
	Sep. 30, 2018USD ($)CompensationPlanshares	Mar. 31, 2018shares	Sep. 30, 2017USD ($)shares	Sep. 30, 2018USD ($)CompensationPlanshares	Sep. 30, 2017USD ($)shares	Dec. 31, 2017shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock-based compensation plans | CompensationPlan	2			2
Annual increase in number of shares available for grant				500,000
Percentage of common shares outstanding				4.00%
Number of shares available for issue, additional shares		446,299
Stock options, vesting period				4 years
Stock options, expire period				10 years
Unrecognized stock-based compensation | $	$ 299,000			$ 299,000
Stock-based compensation expense | $				$ 86,000	$ 162,000
Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized weighted-average period years				2 years 7 months 6 days
Restricted Stock Units (RSUs) and Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock to be received, per restricted stock unit and performance stock unit	1			1
Restricted stock units outstanding	250,000			250,000		392,659
Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) Subject to Performance-based Vesting
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units outstanding	0		0	0	0
Stock-based compensation expense | $	$ 0		$ 0	$ 0	$ 0
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock based compensation | $	$ 150,000			$ 150,000
Stock Incentive Plan 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants	1,545,719			1,545,719

Stock-Based compensation Reflec

Stock-Based compensation Reflected in Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 22	$ 81	$ 86	$ 162
Research and Development Expense
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1	11	6	24
Sales and marketing
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	5	38	15	67
General and Administrative Expense
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 16	$ 32	$ 65	$ 71

Weighted-average Assumptions us

Weighted-average Assumptions used to Estimate Fair Value of Stock Options (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Expected volatility	120.30%	88.20%	120.30%	87.80%
Expected term (in years)	6 years 18 days	6 years 18 days	6 years 18 days	6 years 18 days
Risk-free interest rate	3.00%	2.10%	3.00%	2.10%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Share-Based Activity (Detail)

Share-Based Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Options
Outstanding, beginning balance	992,221
Granted	122,500
Exercised	0
Cancelled	(381,043)
Outstanding, ending balance	733,678	992,221
Vested or expected to vest at September 30, 2018	733,678
Exercisable at September 30, 2018	337,063
Weighted Average Exercise Price
Outstanding, beginning balance	$ 10.71
Granted	0
Exercised	0
Cancelled	5.31
Outstanding, ending balance	4.67	$ 10.71
Vested or expected to vest at September 30, 2018	4.67
Exercisable at September 30, 2018	$ 0
Weighted Average Contractual Life (in Years)
Outstanding at end of period	5 years 11 months 15 days	5 years 8 months 19 days
Vested or expected to vest at September 30, 2018	5 years 11 months 15 days
Exercisable at September 30, 2018	0 years
Aggregate Intrinsic Value
Outstanding at end of period	$ 16	$ 63
Vested or expected to vest at September 30, 2018	16
Exercisable at September 30, 2018	$ 0

Restricted Stock Units and Perf

Restricted Stock Units and Performance Stock Units Activity (Detail) - Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Number of Units
Outstanding, beginning balance	392,659
Granted	0
Exercised	0
Cancelled	(142,659)
Outstanding, ending balance	250,000	392,659
Weighted Average Contractual Life (in years)
Outstanding at end of period	7 years 5 months 23 days	8 years 3 months 7 days
Aggregate Intrinsic Value
Outstanding Aggregate Intrinsic Value	$ 208	$ 429

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)Segment	Sep. 30, 2017USD ($)Customer
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of reportable segments | Segment			1
Long-lived assets	$ 100,000		$ 100,000
Revenue	0	$ 23,000	0	$ 173,000
Major Customers
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 0		$ 0
Sales Revenue, Net | Credit Concentration Risk | Customer One
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of customers | Customer				1
Concentration risk percentage				21.00%
Sales Revenue, Net | Credit Concentration Risk | Customer Two
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of customers | Customer				1
Concentration risk percentage				15.00%
Sales Revenue, Net | Customer Concentration Risk
Revenues from External Customers and Long-Lived Assets [Line Items]
Rebate accrual recognised as revenue		$ 27,000

Product Sales by Geographic Loc

Product Sales by Geographic Location (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 0	$ 23,000	$ 0	$ 173,000
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue		$ 23,000		155,000
Middle East
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue				$ 18,000